CD226 and neoplasm: [205] with their ligands on tumor indicated in parentheses) include PD-1 (PD-L1), KIRs (HLA-C), LAG3 (MHC II), NKG2A/CD94 complex (HLA-E), TIGIT (CD155), TIM3 (Galectin-9), and KLRG-1 (E-cadherin), whereas activating NK receptors include NKG2D (MICA/B), KIRs (HLA-C), CD226 or DNAM-1 (CD112 or Nectin-2, CD155 or PVR), and NKG2C/CD94 complex (HLA-E and Hsp70).